These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37067993)

  • 1. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase.
    Chandhasin C; Dang V; Perabo F; Del Rosario J; Chen YK; Filvaroff E; Stafford JA; Clarke M
    Anticancer Drugs; 2023 Nov; 34(10):1122-1131. PubMed ID: 37067993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in histone demethylase KDM4 as cancer therapeutic targets.
    Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
    FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM4 Demethylases: Structure, Function, and Inhibitors.
    Jiang Y; Liu L; Yang ZQ
    Adv Exp Med Biol; 2023; 1433():87-111. PubMed ID: 37751137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
    Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
    SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
    Berry WL; Janknecht R
    Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances with KDM4 Inhibitors and Potential Applications.
    Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J
    J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM4 inhibitor SD49-7 attenuates leukemia stem cell
    Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y
    Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814
    [No Abstract]   [Full Text] [Related]  

  • 9. The histone demethylase Kdm4 suppresses activation of hepatic stellate cell by inducing MiR-29 transcription.
    Kong M; Wu J; Fan Z; Chen B; Wu T; Xu Y
    Biochem Biophys Res Commun; 2019 Jun; 514(1):16-23. PubMed ID: 31014673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Nguyen A; Nuñez CG; Tran TA; Girard L; Peyton M; Catalan R; Guerena C; Avila K; Drapkin BJ; Chandra R; Minna JD; Martinez ED
    Oncogene; 2024 Sep; 43(38):2885-2899. PubMed ID: 39154123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression.
    Young LC; Hendzel MJ
    Biochem Cell Biol; 2013 Dec; 91(6):369-77. PubMed ID: 24219278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-silico guided chemical exploration of KDM4A fragments hits.
    Lombino J; Vallone R; Cimino M; Gulotta MR; De Simone G; Morando MA; Sabbatella R; Di Martino S; Fogazza M; Sarno F; Coronnello C; De Rosa M; Cipollina C; Altucci L; Perricone U; Alfano C
    Clin Epigenetics; 2023 Dec; 15(1):197. PubMed ID: 38129913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
    Baby S; Gurukkala Valapil D; Shankaraiah N
    Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance.
    Agger K; Nishimura K; Miyagi S; Messling JE; Rasmussen KD; Helin K
    Blood; 2019 Oct; 134(14):1154-1158. PubMed ID: 31434704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family.
    Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U
    J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
    Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ
    Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.
    Labbé RM; Holowatyj A; Yang ZQ
    Am J Transl Res; 2013; 6(1):1-15. PubMed ID: 24349617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
    Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
    Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.
    Pedersen MT; Kooistra SM; Radzisheuskaya A; Laugesen A; Johansen JV; Hayward DG; Nilsson J; Agger K; Helin K
    EMBO J; 2016 Jul; 35(14):1550-64. PubMed ID: 27266524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.